Sinomenine Inhibits Non-Small Cell Lung Cancer via Downregulation of Hexokinases II-Mediated Aerobic Glycolysis

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.2155130620402
   PubMed Web of Science ®Google Scholar
• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454. doi:10.1038/nature2518329364287
   PubMed Web of Science ®Google Scholar
• Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322(8):764–774. doi:10.1001/jama.2019.1105831454018
   PubMed Web of Science ®Google Scholar
• Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725–737. doi:10.1038/s41416-019-0573-831564718
   PubMed Web of Science ®Google Scholar
• Tun AM, Thein KZ, Thein WL, Guevara E. Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Future Sci OA. 2019;5(9):FSO421. doi:10.2144/fsoa-2019-008131608159
   PubMed Web of Science ®Google Scholar
• Bianco A, Perrotta F, Barra G, Malapelle U, Rocco D, De Palma R. Prognostic factors and biomarkers of responses to immune checkpoint inhibitors in lung cancer. Int J Mol Sci. 2019;20:19. doi:10.3390/ijms20194931
   Web of Science ®Google Scholar
• Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27:441–464. doi:10.1146/annurev-cellbio-092910-15423721985671
   PubMed Web of Science ®Google Scholar
• Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol. 2003;206(Pt 12):2049–2057. doi:10.1242/jeb.0024112756287
   PubMed Web of Science ®Google Scholar
• Zhou L, Li M, Yu X, Gao F, Li W. Repression of hexokinases II-mediated glycolysis contributes to piperlongumine-induced tumor suppression in non-small cell lung cancer cells. Int J Biol Sci. 2019;15(4):826–837. doi:10.7150/ijbs.3174930906213
   PubMed Web of Science ®Google Scholar
• Wolf A, Agnihotri S, Micallef J, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 2011;208(2):313–326. doi:10.1084/jem.2010147021242296
   PubMed Web of Science ®Google Scholar
• Katagiri M, Karasawa H, Takagi K, et al. Hexokinase 2 in colorectal cancer: a potent prognostic factor associated with glycolysis, proliferation and migration. Histol Histopathol. 2017;32(4):351–360.27363977
   PubMed Web of Science ®Google Scholar
• Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem. 2002;277(9):7610–7618. doi:10.1074/jbc.M10995020011751859
   PubMed Web of Science ®Google Scholar
• Shi T, Ma Y, Cao L, et al. B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. Cell Death Dis. 2019;10(4):308. doi:10.1038/s41419-019-1549-630952834
   PubMed Web of Science ®Google Scholar
• Zhong JT, Zhou SH. Warburg effect, hexokinase-II, and radioresistance of laryngeal carcinoma. Oncotarget. 2017;8(8):14133–14146. doi:10.18632/oncotarget.1304427823965
   PubMedGoogle Scholar
• Li W, Yu X, Xia Z, et al. Repression of Noxa by Bmi1 contributes to deguelin-induced apoptosis in non-small cell lung cancer cells. J Cell Mol Med. 2018;22(12):6213–6227. doi:10.1111/jcmm.1390830255595
   PubMed Web of Science ®Google Scholar
• Li W, Yu X, Tan S, Liu W, Zhou L, Liu H. Oxymatrine inhibits non-small cell lung cancer via suppression of EGFR signaling pathway. Cancer Med. 2018;7(1):208–218. doi:10.1002/cam4.126929239135
   PubMed Web of Science ®Google Scholar
• Li W, Ma X, Li N, et al. Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway. Exp Cell Res. 2016;349(2):320–327. doi:10.1016/j.yexcr.2016.11.00227829129
   PubMed Web of Science ®Google Scholar
• Liu H, Li W, Yu X, et al. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis. Oncotarget. 2016;7(35):56338–56354. doi:10.18632/oncotarget.1084127472460
   PubMedGoogle Scholar
• Sun Z, Zheng L, Liu X, Xing W, Liu X. Sinomenine inhibits the growth of melanoma by enhancement of autophagy via PI3K/AKT/mTOR inhibition. Drug Des Devel Ther. 2018;12:2413–2421. doi:10.2147/DDDT.S155798
   PubMed Web of Science ®Google Scholar
• Fu S, Jin L, Gong T, et al. Effect of sinomenine hydrochloride on radiosensitivity of esophageal squamous cell carcinoma cells. Oncol Rep. 2018;39(4):1601–1608. doi:10.3892/or.2018.622829393484
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu C, Tan T, Li S, Tang S, Chen X. Sinomenine sensitizes human gastric cancer cells to cisplatin through negative regulation of PI3K/AKT/Wnt signaling pathway. Anticancer Drugs. 2019;30(10):983–990. doi:10.1097/CAD.000000000000083431609766
   PubMed Web of Science ®Google Scholar
• Yuan H, Zhang J, Li F, Li W, Wang H. Sinomenine exerts antitumour effect in gastric cancer cells via enhancement of miR-204 expression. Basic Clin Pharmacol Toxicol. 2019;125(5):450–459. doi:10.1111/bcpt.1328531243880
   PubMed Web of Science ®Google Scholar
• Gao G, Liang X, Ma W. Sinomenine restrains breast cancer cells proliferation, migration and invasion via modulation of miR-29/PDCD-4 axis. Artif Cells Nanomed Biotechnol. 2019;47(1):3839–3846. doi:10.1080/21691401.2019.166686131556312
   PubMed Web of Science ®Google Scholar
• Xu F, Li Q, Wang Z, Cao X. Sinomenine inhibits proliferation, migration, invasion and promotes apoptosis of prostate cancer cells by regulation of miR-23a. Biomed Pharmacother. 2019;112:108592. doi:10.1016/j.biopha.2019.01.05330784907
   PubMed Web of Science ®Google Scholar
• Zhang D, Dong Y, Zhao Y, et al. Sinomenine hydrochloride sensitizes cervical cancer cells to ionizing radiation by impairing DNA damage response. Oncol Rep. 2018;40(5):2886–2895. doi:10.3892/or.2018.669330226618
   PubMed Web of Science ®Google Scholar
• Zhao B, Liu L, Mao J, et al. Sinomenine hydrochloride attenuates the proliferation, migration, invasiveness, angiogenesis and epithelial-mesenchymal transition of clear-cell renal cell carcinoma cells via targeting Smad in vitro. Biomed Pharmacother. 2017;96:1036–1044. doi:10.1016/j.biopha.2017.11.12329198924
   PubMed Web of Science ®Google Scholar
• He X, Maimaiti M, Jiao Y, Meng X, Li H. Sinomenine induces G1-phase cell cycle arrest and apoptosis in malignant glioma cells via downregulation of sirtuin 1 and induction of p53 acetylation. Technol Cancer Res Treat. 2018;17:1533034618770305. doi:10.1177/153303461877030529756546
   PubMed Web of Science ®Google Scholar
• Jiang Y, Jiao Y, Liu Y, et al. Sinomenine hydrochloride inhibits the metastasis of human glioblastoma cells by suppressing the expression of matrix metalloproteinase-2/-9 and reversing the endogenous and exogenous epithelial-mesenchymal transition. Int J Mol Sci. 2018;19:3.
   Web of Science ®Google Scholar
• Deng F, Ma YX, Liang L, Zhang P, Feng J. The pro-apoptosis effect of sinomenine in renal carcinoma via inducing autophagy through inactivating PI3K/AKT/mTOR pathway. Biomed Pharmacother. 2018;97:1269–1274. doi:10.1016/j.biopha.2017.11.06429145153
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.01321376230
   PubMed Web of Science ®Google Scholar
• Abbaszadeh Z, Cesmeli S, Biray Avci C. Crucial players in glycolysis: cancer progress. Gene. 2019;144158.31629815
   PubMed Web of Science ®Google Scholar
• Payen VL, Porporato PE, Baselet B, Sonveaux P. Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway. Cell Mol Life Sci. 2016;73(7):1333–1348. doi:10.1007/s00018-015-2098-526626411
   PubMed Web of Science ®Google Scholar
• Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152. doi:10.1186/1476-4598-12-15224298908
   PubMed Web of Science ®Google Scholar
• Patra KC, Wang Q, Bhaskar PT, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013;24(2):213–228. doi:10.1016/j.ccr.2013.06.01423911236
   PubMed Web of Science ®Google Scholar
• Liu W, Li W, Liu H, Yu X. Xanthohumol inhibits colorectal cancer cells via downregulation of Hexokinases II-mediated glycolysis. Int J Biol Sci. 2019;15(11):2497–2508. doi:10.7150/ijbs.3748131595166
   PubMed Web of Science ®Google Scholar
• Gao F, Li M, Liu WB, et al. Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2mediated glycolysis. Oncol Rep. 2015;33(3):1533–1539. doi:10.3892/or.2015.372725591943
   PubMed Web of Science ®Google Scholar
• Li W, Gao F, Ma X, Wang R, Dong X, Wang W. Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis. Oncotarget. 2017;8(20):32586–32599. doi:10.18632/oncotarget.1593728427230
   PubMedGoogle Scholar
• Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169(3):381–405. doi:10.1016/j.cell.2017.04.00128431241
   PubMed Web of Science ®Google Scholar
• Yu X, Wang R, Zhang Y, et al. Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin. Oncogene. 2019;38(50):7457–7472. doi:10.1038/s41388-019-0955-731435020
   PubMed Web of Science ®Google Scholar
• Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol. 2007;27(21):7381–7393. doi:10.1128/MCB.00440-0717785433
   PubMed Web of Science ®Google Scholar
• Masoud GN, Li W. HIF-1alpha pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5(5):378–389. doi:10.1016/j.apsb.2015.05.00726579469
   PubMed Web of Science ®Google Scholar
• Londhe P, Yu PY, Ijiri Y, et al. Classical NF-kappaB metabolically reprograms sarcoma cells through regulation of Hexokinase 2. Front Oncol. 2018;8:104. doi:10.3389/fonc.2018.0010429696133
   PubMed Web of Science ®Google Scholar
• Song L, Liu D, Zhao Y, et al. Sinomenine inhibits breast cancer cell invasion and migration by suppressing NF-kappaB activation mediated by IL-4/miR-324-5p/CUEDC2 axis. Biochem Biophys Res Commun. 2015;464(3):705–710. doi:10.1016/j.bbrc.2015.07.00426166821
   PubMed Web of Science ®Google Scholar